1. Cell Cycle/DNA Damage Stem Cell/Wnt Autophagy Apoptosis
  2. CDK Wnt Autophagy Apoptosis
  3. Wogonin

Wogonin is a naturally occurring mono-flavonoid, can inhibit the activity of CDK8 and Wnt, and exhibits anti-inflammatory and anti-tumor effects.

For research use only. We do not sell to patients.

Wogonin Chemical Structure

Wogonin Chemical Structure

CAS No. : 632-85-9

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
50 mg In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 16 publication(s) in Google Scholar

Other Forms of Wogonin:

Top Publications Citing Use of Products

    Wogonin purchased from MedChemExpress. Usage Cited in: J Immunol Res. 2020 Jun 1;2020:3032425.  [Abstract]

    Dose-dependent inhibition of STAT3 and ERK phosphorylation by Wogonin in LPS-treated B cells. CD19+ B cells were cultured with LPS for 6 h in the presence or absence of Wogonin (12.5, 25, and 50 μM) are analyzed and quantified by Western Blot.
    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Wogonin is a naturally occurring mono-flavonoid, can inhibit the activity of CDK8 and Wnt, and exhibits anti-inflammatory and anti-tumor effects.

    IC50 & Target[1]

    CDK8

     

    Cellular Effect
    Cell Line Type Value Description References
    A549 IC50
    15.8 μM
    Compound: 1
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 28117202]
    A549 IC50
    20.1 μM
    Compound: 1
    Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 28987604]
    A549 IC50
    42.3 μM
    Compound: Wogonin
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 31238183]
    B16 IC50
    26.4 μM
    Compound: 1
    Cytotoxicity in mouse B16 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity in mouse B16 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 28987604]
    BV-2 IC50
    7.8 μM
    Compound: Wgn, Wogonin
    Inhibition of iNOS-induced NO production in LPS-stimulated mouse BV2 cells after 24 hrs
    Inhibition of iNOS-induced NO production in LPS-stimulated mouse BV2 cells after 24 hrs
    [PMID: 22366656]
    DLD-1 IC50
    36.87 μM
    Compound: 3; Wogonin
    Antiproliferative activity against human DLD1 cells after 48 hrs by MTT assay
    Antiproliferative activity against human DLD1 cells after 48 hrs by MTT assay
    10.1039/C5MD00163C
    HCT-116 IC50
    27.3 μM
    Compound: Wogonin
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 31238183]
    HepG2 IC50
    17.6 μM
    Compound: Wogonin
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 31238183]
    HepG2 IC50
    19 μM
    Compound: 1
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 28117202]
    HepG2 IC50
    19.5 μM
    Compound: 1
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 28987604]
    HepG2 IC50
    37.89 μM
    Compound: 3; Wogonin
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    10.1039/C5MD00163C
    HepG2 2.2.15 IC50
    4 μg/mL
    Compound: 1
    Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV e antigen secretion after 9 days
    Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV e antigen secretion after 9 days
    [PMID: 24549242]
    HT-29 IC50
    39.55 μM
    Compound: 3; Wogonin
    Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay
    10.1039/C5MD00163C
    HUVEC IC50
    105 μM
    Compound: 3
    Inhibition of trypsin-induced elevation in PAI1 production in HUVEC by ELISA
    Inhibition of trypsin-induced elevation in PAI1 production in HUVEC by ELISA
    [PMID: 9214730]
    MCF7 IC50
    28 μM
    Compound: 1
    Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 28987604]
    MCF7 IC50
    30 nM
    Compound: 44
    Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay
    [PMID: 36205223]
    MCF7 IC50
    30 μM
    Compound: Wagonin
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
    [PMID: 32707525]
    MCF7 IC50
    30 μM
    Compound: Wogonin
    Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay
    [PMID: 31300317]
    MV4-11 IC50
    30.7 μM
    Compound: Wogonin
    Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 31238183]
    RAW264.7 IC50
    1.07 μM
    Compound: Wogonin
    Inhibition of COX2-mediated PGE2 production in LPS-stimulated mouse RAW264.7 cells by enzyme immunoassay
    Inhibition of COX2-mediated PGE2 production in LPS-stimulated mouse RAW264.7 cells by enzyme immunoassay
    [PMID: 19233646]
    Sf21 IC50
    12.3 μM
    Compound: 22
    Inhibition of recombinant human full length C-terminal His6-tagged and N-terminal GST-tagged CDK7/cyclinH/MAT1 expressed in baculovirus Sf21 insect cells after 40 mins in presence of [gamma-32P]ATP by scintillation counting analysis
    Inhibition of recombinant human full length C-terminal His6-tagged and N-terminal GST-tagged CDK7/cyclinH/MAT1 expressed in baculovirus Sf21 insect cells after 40 mins in presence of [gamma-32P]ATP by scintillation counting analysis
    [PMID: 30733087]
    Sf9 IC50
    190 nM
    Compound: Wogonin
    Inhibition of human recombinant N-terminal GST-tagged CDK9 (2 to 372 residues)/N-terminal GST-tagged cyclin-T1 (2 to 726 residues) expressed in baculovirus infected Sf9 insect cells using peptide as substrate after 40 mins in presence of gamma-[32]P-ATP b
    Inhibition of human recombinant N-terminal GST-tagged CDK9 (2 to 372 residues)/N-terminal GST-tagged cyclin-T1 (2 to 726 residues) expressed in baculovirus infected Sf9 insect cells using peptide as substrate after 40 mins in presence of gamma-[32]P-ATP b
    [PMID: 31238183]
    Sf9 IC50
    190 nM
    Compound: 22
    Inhibition of human recombinant N-terminal GST-tagged CDK9 (2 to 372 residues) expressed in baculovirus infected Sf9 insect cells co-expressing human cyclin T1 (2 to 726 residues) after 40 mins in presence of [gamma-32P]ATP by scintillation counting analy
    Inhibition of human recombinant N-terminal GST-tagged CDK9 (2 to 372 residues) expressed in baculovirus infected Sf9 insect cells co-expressing human cyclin T1 (2 to 726 residues) after 40 mins in presence of [gamma-32P]ATP by scintillation counting analy
    [PMID: 30733087]
    SW480 IC50
    35.06 μM
    Compound: 3; Wogonin
    Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay
    Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay
    10.1039/C5MD00163C
    In Vitro

    Wogonin (0-200 μM) exhibits a dose- and time- dependent reduces in cell viability of caco-2, SW1116 and HCT116 cells. Wogonin (10-40 μM) induces G1 phase arrest in HCT-116 cells. Wogonin also supresses Wnt signaling pathway in HCT116 cells. Wogonin interfers in the activity of transcription factor TCF/Lef family. Moreover, Wogonin inhibits β-catenin-mediated transcription through suppressing the activity of CDK8[1]. Wogonin shows cytotoxic and antiproliferative effects on HeLa cells. Wogonin (90 µM) induces cell cycle arrest at G0-G1 phase, and suppresses the levels of cyclin D1 and Cdk4 markedly in HeLa cells[2]. Wogonin (1.25, 2.5, 5, 10, 20 μg/ml) suppresses EtOH-induced inflammatory response in RAW264.7 cells[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    In Vivo

    Wogonin (30, 60 mg/kg) reduces tumor growth of HCT116 cells in a xenograft model[1]. Wogonin (25, 50, 100 mg/kg) protects against liver injury and pathological characteristics of ALD in mice. Wogonin activates PPAR-γ expression in mice with ALD and EtOH induced RAW264.7 cells[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Molecular Weight

    284.26

    Formula

    C16H12O5

    CAS No.
    Appearance

    Solid

    Color

    Light yellow to yellow

    SMILES

    O=C1C=C(C2=CC=CC=C2)OC3=C(OC)C(O)=CC(O)=C13

    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage

    4°C, protect from light

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    Solvent & Solubility
    In Vitro: 

    DMSO : 62.5 mg/mL (219.87 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.5179 mL 17.5895 mL 35.1791 mL
    5 mM 0.7036 mL 3.5179 mL 7.0358 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: 2.08 mg/mL (7.32 mM); Suspended solution; Need ultrasonic

      This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  0.5% CMC-Na/saline water

      Solubility: 24 mg/mL (84.43 mM); Suspended solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.92%

    References
    Cell Assay
    [1]

    HCT116 cells are planted on a 96-well plate (1 × 105 cells per well). Different concentrations of wogonin are added and incubated for 24 h. Subsequently, 20 μL of MTT solution (5 mg/mL) is transferred to each well and the plates are incubated for 4 h at 37°C and 5% CO2. The supernatant is aspirated off and 100 μL DMSO is added to dissolve the formazan crystal. The mixture is shaken and measured at 570 nm using a universal microplate reader.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [3]

    C57BL/6 mice, male, 6-8 weeks old, weighing 18-22 g mice are housed at comfortable environment and are acclimatized for 3 days before the experiment. A total of 48 mice are randomLy divided into six groups of 8 animals, respectively control diet (CD)-fed mice, EtOH-fed mice, wogonin-treated mice at the dose of 25, 50, 100 mg/kg/day and the positive (dexamethasone, 1 mg/kg/day)-treated mice. Modeling process has a total of 16 days including a liquid diet adaptation period for 3 days and modeling for 13 days. The EtOH-fed mice are fed containing 5% v/v ethanol liquid diets adding certain vitamin and choline for 16 days, and mice are gavaged with a single binge ethanol administration (5 g/kg, body weight, 20% ethanol) at last day. At the same time, the wogonin-treated mice and the positive-treated mice are not only plus the ethanol administration, but also plus the medicines by gavage daily, whereas the CD-fed mice are fed with control liquid diets and gavaged with isocaloric maltose-dextrin at last day. All diets are prepared fresh daily. 9 h after the last gavage alcohol, mice are sacrificed under anaesthesia, the liver tissues and blood are collected for further analysis.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 3.5179 mL 17.5895 mL 35.1791 mL 87.9477 mL
    5 mM 0.7036 mL 3.5179 mL 7.0358 mL 17.5895 mL
    10 mM 0.3518 mL 1.7590 mL 3.5179 mL 8.7948 mL
    15 mM 0.2345 mL 1.1726 mL 2.3453 mL 5.8632 mL
    20 mM 0.1759 mL 0.8795 mL 1.7590 mL 4.3974 mL
    25 mM 0.1407 mL 0.7036 mL 1.4072 mL 3.5179 mL
    30 mM 0.1173 mL 0.5863 mL 1.1726 mL 2.9316 mL
    40 mM 0.0879 mL 0.4397 mL 0.8795 mL 2.1987 mL
    50 mM 0.0704 mL 0.3518 mL 0.7036 mL 1.7590 mL
    60 mM 0.0586 mL 0.2932 mL 0.5863 mL 1.4658 mL
    80 mM 0.0440 mL 0.2199 mL 0.4397 mL 1.0993 mL
    100 mM 0.0352 mL 0.1759 mL 0.3518 mL 0.8795 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Salutation

    Applicant Name *

     

    Email Address *

    Phone Number *

     

    Organization Name *

    Department *

     

    Requested quantity *

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Wogonin
    Cat. No.:
    HY-N0400
    Quantity:
    MCE Japan Authorized Agent: